PMID- 24019878
OWN - NLM
STAT- MEDLINE
DCOM- 20140516
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 9
DP  - 2013
TI  - Antidepressant-like effects of erythropoietin: a focus on behavioural and 
      hippocampal processes.
PG  - e72813
LID - 10.1371/journal.pone.0072813 [doi]
LID - e72813
AB  - Depression is a chronic and debilitating condition with a significant degree of 
      relapse and treatment resistance that could stem, at least in part, from 
      disturbances of neuroplasticity. This has led to an increased focus on treatment 
      strategies that target brain derived neurotrophic factor (BDNF), synaptic 
      plasticity and adult neurogenesis. In the current study we aimed to assess 
      whether erythropoietin (EPO) would have antidepressant-like effects given its 
      already established pro-trophic actions. In particular, we assessed whether EPO 
      would diminish the deleterious effects of a social stressor in mice. Indeed, EPO 
      induced anxiolytic and antidepressant-like responses in a forced swim test, open 
      field, elevated-plus maze, and a novelty test, and appeared to blunt some of the 
      negative behavioural effects of a social stressor. Furthermore, EPO promoted 
      adult hippocampal neurogenesis, an important feature of effective 
      antidepressants. Finally, a separate study using the mTOR inhibitor rapamycin 
      revealed that antagonizing this pathway prevented the impact of EPO upon forced 
      swim performance. These data are consistent with previous findings showing that 
      the mTOR pathway and its neurogenic and synaptogenic effects might mediate the 
      behavioral consequences of antidepressant agents. Our findings further highlight 
      EPO as a possible adjunct treatment for affective disorders, as well as other 
      stressor associated disorders of impaired neuroplasticity.
FAU - Osborn, Meagan
AU  - Osborn M
AD  - Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada.
FAU - Rustom, Nazneen
AU  - Rustom N
FAU - Clarke, Melanie
AU  - Clarke M
FAU - Litteljohn, Darcy
AU  - Litteljohn D
FAU - Rudyk, Chris
AU  - Rudyk C
FAU - Anisman, Hymie
AU  - Anisman H
FAU - Hayley, Shawn
AU  - Hayley S
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130903
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antidepressive Agents)
RN  - 11096-26-7 (Erythropoietin)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*pharmacology
MH  - Behavior, Animal/*drug effects
MH  - Erythropoietin/*pharmacology
MH  - Hippocampus/*drug effects/physiology
MH  - Male
MH  - Maze Learning
MH  - Mice
MH  - Sirolimus/pharmacology
MH  - Swimming
PMC - PMC3760922
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/09/11 06:00
MHDA- 2014/05/17 06:00
PMCR- 2013/09/03
CRDT- 2013/09/11 06:00
PHST- 2013/02/07 00:00 [received]
PHST- 2013/07/19 00:00 [accepted]
PHST- 2013/09/11 06:00 [entrez]
PHST- 2013/09/11 06:00 [pubmed]
PHST- 2014/05/17 06:00 [medline]
PHST- 2013/09/03 00:00 [pmc-release]
AID - PONE-D-13-05680 [pii]
AID - 10.1371/journal.pone.0072813 [doi]
PST - epublish
SO  - PLoS One. 2013 Sep 3;8(9):e72813. doi: 10.1371/journal.pone.0072813. eCollection 
      2013.